Nuvilex (PMCB) Competitors $1.11 +0.00 (+0.40%) As of 01:14 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PMCB vs. SCYX, FGEN, DYAI, ENLV, CALC, GBIO, MIRA, FBLG, NRSN, and OVIDShould you be buying Nuvilex stock or one of its competitors? The main competitors of Nuvilex include SCYNEXIS (SCYX), FibroGen (FGEN), Dyadic International (DYAI), Enlivex Therapeutics (ENLV), CalciMedica (CALC), Generation Bio (GBIO), MIRA Pharmaceuticals (MIRA), FibroBiologics (FBLG), NeuroSense Therapeutics (NRSN), and Ovid Therapeutics (OVID). These companies are all part of the "pharmaceutical products" industry. Nuvilex vs. Its Competitors SCYNEXIS FibroGen Dyadic International Enlivex Therapeutics CalciMedica Generation Bio MIRA Pharmaceuticals FibroBiologics NeuroSense Therapeutics Ovid Therapeutics Nuvilex (NASDAQ:PMCB) and SCYNEXIS (NASDAQ:SCYX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, dividends, institutional ownership, analyst recommendations, earnings and valuation. Which has higher earnings and valuation, PMCB or SCYX? Nuvilex has higher earnings, but lower revenue than SCYNEXIS. SCYNEXIS is trading at a lower price-to-earnings ratio than Nuvilex, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNuvilexN/AN/A$330K$0.741.50SCYNEXIS$3.75M7.84-$21.29M-$0.56-1.34 Do institutionals and insiders believe in PMCB or SCYX? 34.2% of Nuvilex shares are owned by institutional investors. Comparatively, 54.4% of SCYNEXIS shares are owned by institutional investors. 10.2% of Nuvilex shares are owned by insiders. Comparatively, 4.9% of SCYNEXIS shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Is PMCB or SCYX more profitable? Nuvilex has a net margin of 0.00% compared to SCYNEXIS's net margin of -1,030.04%. Nuvilex's return on equity of 0.51% beat SCYNEXIS's return on equity.Company Net Margins Return on Equity Return on Assets NuvilexN/A 0.51% 0.35% SCYNEXIS -1,030.04%-53.47%-32.86% Which has more volatility & risk, PMCB or SCYX? Nuvilex has a beta of -0.42, meaning that its stock price is 142% less volatile than the S&P 500. Comparatively, SCYNEXIS has a beta of 1.57, meaning that its stock price is 57% more volatile than the S&P 500. Does the media favor PMCB or SCYX? In the previous week, Nuvilex and Nuvilex both had 1 articles in the media. Nuvilex's average media sentiment score of 1.87 equaled SCYNEXIS'saverage media sentiment score. Company Overall Sentiment Nuvilex Very Positive SCYNEXIS Very Positive SummaryNuvilex beats SCYNEXIS on 7 of the 10 factors compared between the two stocks. Get Nuvilex News Delivered to You Automatically Sign up to receive the latest news and ratings for PMCB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PMCB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PMCB vs. The Competition Export to ExcelMetricNuvilexMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.62M$2.44B$5.56B$9.30BDividend YieldN/A1.79%4.23%4.03%P/E Ratio1.509.1628.6119.64Price / SalesN/A735.94437.49188.30Price / CashN/A164.3436.0257.93Price / Book0.344.688.185.63Net Income$330K$30.99M$3.23B$257.73M7 Day PerformanceN/A0.57%-0.25%0.07%1 Month Performance9.90%7.91%5.40%8.32%1 Year Performance-45.85%-5.94%26.35%13.78% Nuvilex Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PMCBNuvilex2.9923 of 5 stars$1.11+0.4%N/A-46.6%$7.62MN/A1.504Gap UpSCYXSCYNEXIS1.0539 of 5 stars$0.76-7.2%N/A-65.1%$29.66M$2.63M-1.3660Positive NewsFGENFibroGen4.6966 of 5 stars$7.32-4.8%$250.00+3,315.3%-72.4%$29.57M$29.62M-2.93570Positive NewsDYAIDyadic International3.1294 of 5 stars$0.98+1.1%$6.00+512.1%-31.0%$29.50M$3.34M-4.907Positive NewsENLVEnlivex Therapeutics2.8334 of 5 stars$1.23-3.9%$10.00+713.0%-12.8%$29.09MN/A-1.8670CALCCalciMedica2.8705 of 5 stars$2.05-11.6%$16.00+680.5%-57.4%$28.64MN/A-1.3130Gap UpGBIOGeneration Bio3.9152 of 5 stars$0.43-3.2%$7.33+1,621.4%-85.5%$28.56M$19.89M-0.39150News CoverageGap UpHigh Trading VolumeMIRAMIRA Pharmaceuticals2.4343 of 5 stars$1.66+7.8%$14.00+743.4%+124.3%$28.09MN/A-3.252FBLGFibroBiologics3.7837 of 5 stars$0.70+8.9%$13.00+1,764.9%-86.1%$27.66MN/A-3.3210NRSNNeuroSense Therapeutics2.4624 of 5 stars$1.98-1.0%$14.00+607.1%+114.3%$27.06MN/A-3.6710OVIDOvid Therapeutics4.636 of 5 stars$0.37-7.3%$3.13+749.2%-60.8%$26.17M$570K-1.0560Gap Down Related Companies and Tools Related Companies SCYX Competitors FGEN Competitors DYAI Competitors ENLV Competitors CALC Competitors GBIO Competitors MIRA Competitors FBLG Competitors NRSN Competitors OVID Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PMCB) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredDrilling With a $3.5B Discovery Partner in Its CornerA small-cap explorer is about to drill for high-grade gold in a region known for multi-million-ounce discoveri...The Tomorrow Investor | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvilex Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuvilex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PMCB Stock Alerts